SavedAdd your journal

Journals / Nöropsikiyatri Arşivi / 2009 / Cilt: 46 - Sayı: 4

Tedaviye dirençli tourette sendromunda yüksek doz risperidon bir seçenek midir?

Is high dose risperidone an option for treatment-resistant tourette syndrome?

Mazluk ÇÖPÜR
Baki ARPACI
Ş. Senem BAŞGÜL
Pages
206–208
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This case was thought to be important in showing that high dose risperidone might be effective in treatment-resistant TS cases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Gilles de la Tourette syndrome (TS) is a chronic neuropsychiatric disorder that begins in childhood, in which multiple motor tics and one or more vocal tics are seen concomitantly.
📊
Key Findings & Data:Significant reductions in tics were observed with 8 mg/day risperidone treatment in this case who failed to respond to many neuroleptics.
💡
Conclusion & Impact:This case was thought to be important in showing that high dose risperidone might be effective in treatment-resistant TS cases.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Antipsikotik ajanlar · Tourette sendromu · Ergen

Abstract

Gilles de la Tourette syndrome (TS) is a chronic neuropsychiatric disorder that begins in childhood, in which multiple motor tics and one or more vocal tics are seen concomitantly. In this text, the treatment course of a severe TS case, with complete daily functioning loss, is described. Significant reductions in tics were observed with 8 mg/day risperidone treatment in this case who failed to respond to many neuroleptics. The Yale Global Tic Severity Scale (Y-GTSS) score, which was 85 before treatment, declined to 48. In our case, who used this dosing regimen for six months, the reduced tic status continued after the dose was switched to 6 mg/day, the reduction status was observed to go on after six months. No significant side effect was observed. This case was thought to be important in showing that high dose risperidone might be effective in treatment-resistant TS cases.

Özet

Gilles de la Tourette sendromu (TS) çocukluk çağında başlayan, çoğul motor tik ve bir veya daha fazla ses tikinin eşlik ettiği kronik bir nöropsikiyatrik bozukluktur. Bu sunumda günlük fonksiyonlarını yapamayacak kadar ağır bir TS olgusunun tedavisi anlatılmaktadır. Birçok nöroleptik ile tedaviye cevap vermeyen olgumuzun tiklerinde, 8 mgr- gün risperidon tedavisi ile azalma görülmüştür. Tedaviden önce 85 olan Yale Genel Tik Ağırlığını Derecelendirme Ölçeği (YGTDÖ) skoru tedaviden sonra 48 olarak tespit edilmiştir. Olgumuz bu dozu altı ay boyunca kullanmış, doz 6 mgr-gün olarak azaltıldıktan altı ay sonra da tiklerdeki azalma devam etmiştir. Önemli bir yan etki ortaya çıkmamıştır. Bu olgu tedaviye dirençli TS olgularının tedavisinde yüksek doz risperidonun etkili olabileceğini düşündürmektedir.

🔖

Cite This Article

ÇÖPÜR, M., ARPACI, B., BAŞGÜL, Ş. S. (2009). Tedaviye dirençli tourette sendromunda yüksek doz risperidon bir seçenek midir?. Nöropsikiyatri Arşivi, Cilt: 46 - Sayı: 4, 206–208. https://ajindex.com/articles/292748

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Kossoff EH, Sınger HS. Tourette Syndrome: Clinical characteristics and current management strategies. Paediatr Drugs 2001; 3:355-63
  2. Scahill L, Erenberg G, Berlin CM Jr et al. Contemporary assesment a pharmacotherapy of Tourette syndrome. NeuroRx 2006; 3:192-206
  3. Sindø I, Jørgensen JI. Treatment of tics in Tourette syndrome with atypical antipsychotic drugs. Ugeskr Laeger. 2002; 164:3755-9
  4. Silay Y, Jankovic J. Emerging drugs in Tourette syndrome. Expert Opin Emerg Drugs. 2005; 10:365-80
  5. Jiménez-Jiménez FJ, García-Ruiz PJ. Pharmacological options for the treatment of Tourette's disorder. Drugs 2001; 61:2207-20
  6. Dion Y, Annable L, Sandor P et al. Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psycopharmacol 2002; 22:31-9
  7. Bhadrinath BR. Olanzapine in Tourette’s syndrome. Br J Psychiatry 1998; 172:366
  8. Sallee FR, Kurlan R, Goetz CG et al. Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000; 39:292-9
  9. Párraga HC, Párraga I, Woodward RL et al. Quetiapine treatment of children with Tourette’s syndrome: report of two cases. J Child Adolesc Psychopharmacol 2001; 11:187-91
  10. Schmider J, Hoff P. Clozapine in Tourette’s syndrome. J Clin Psychopharmacol 1998; 18:88-9
  11. Jankovic J. Tourette Syndrome. In: Gilman S, ed. MedLink Neurology. San Diego, CA: MedLink Corporation; 2009
  12. Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with Tourette’s disorder. J Child Adolesc Psychopharmacol 2003; 13:295-9
  13. Copur M, Arpaci B, Demir T et al. Clinical effectiveness of quetiapine in children and adolescents with Tourette's syndrome: a retrospective case-note survey. Clin Drug Investig 2007; 27:123-30
  14. Fahn S, Jankovic J. Tikler ve Tourette Sendromu. Hareket Bozuklukları:İlkeler ve uygulamalar içinde
  15. Baskı. Akbostancı C. çev.editörü. İstanbul Veri Medikal Yayıncılık; 2008; s.409-42
  16. Leckman JF, Ridle MA, Hardin MT et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated-scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989; 28:566–73
  17. Müller Vahl KR. The treatment of Tourette’s syndrome:current opinions. Expert Opin Pharmacother 2002; 3:899-914
  18. Singer HS. Neurobiology of Tourette syndrome.Neurol. Clin 1997; 15:357-79
  19. Mink JW. Neurobiology of basal ganglia circiut in Tourette Syndrome: faulty inhibition of unwanted motor patterns?